

Fang Wu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5567320/publications.pdf>

Version: 2024-02-01

49
papers

1,060
citations

567144

15
h-index

477173

29
g-index

56
all docs

56
docs citations

56
times ranked

1581
citing authors

#	ARTICLE	IF	CITATIONS
1	C-Reactive Protein Level May Predict the Risk of COVID-19 Aggravation. Open Forum Infectious Diseases, 2020, 7, ofaa153.	0.4	194
2	Low high-density lipoprotein level is correlated with the severity of COVID-19 patients: an observational study. Lipids in Health and Disease, 2020, 19, 204.	1.2	110
3	DNA methyltransferase inhibitors combination therapy for the treatment of solid tumor: mechanism and clinical application. Clinical Epigenetics, 2021, 13, 166.	1.8	85
4	Using Artificial Intelligence (Watson for Oncology) for Treatment Recommendations Amongst Chinese Patients with Lung Cancer: Feasibility Study. Journal of Medical Internet Research, 2018, 20, e11087.	2.1	81
5	The Resistance Mechanisms and Treatment Strategies for ALK-Rearranged Non-Small Cell Lung Cancer. Frontiers in Oncology, 2021, 11, 713530.	1.3	54
6	Crosstalk of MicroRNAs and Oxidative Stress in the Pathogenesis of Cancer. Oxidative Medicine and Cellular Longevity, 2020, 2020, 1-13.	1.9	45
7	Rab25 GTPase: Functional roles in cancer. Oncotarget, 2017, 8, 64591-64599.	0.8	43
8	SOX9/miR-130a/CTR1 axis modulates DDP-resistance of cervical cancer cell. Cell Cycle, 2018, 17, 448-458.	1.3	41
9	Ultrasensitive DNA hypermethylation detection using plasma for early detection of NSCLC: a study in Chinese patients with very small nodules. Clinical Epigenetics, 2020, 12, 39.	1.8	37
10	The key to immunotherapy: how to choose better therapeutic biomarkers for patients with non-small cell lung cancer. Biomarker Research, 2022, 10, 9.	2.8	28
11	Trans-3,5,4-trimethoxystilbene reduced gefitinib resistance in NSCLCs via suppressing MAPK/Akt/Bcl-2 pathway by upregulation of miR-345 and miR-498. Journal of Cellular and Molecular Medicine, 2019, 23, 2431-2441.	1.6	27
12	Anti-Angiogenic Therapy in the Treatment of Non-Small Cell Lung Cancer. OncoTargets and Therapy, 2020, Volume 13, 12113-12129.	1.0	25
13	Multiple Primary Lung Cancers: A New Challenge in the Era of Precision Medicine. Cancer Management and Research, 2020, Volume 12, 10361-10375.	0.9	22
14	Genomic profiles and their associations with TMB, PD-L1 expression, and immune cell infiltration landscapes in synchronous multiple primary lung cancers. , 2021, 9, e003773.		21
15	Chronic Stress: Impacts on Tumor Microenvironment and Implications for Anti-Cancer Treatments. Frontiers in Cell and Developmental Biology, 2021, 9, 777018.	1.8	20
16	circRACGAP1 promotes non-small cell lung cancer proliferation by regulating miR-144-5p/CDKL1 signaling pathway. Cancer Gene Therapy, 2021, 28, 197-211.	2.2	19
17	Immune Microenvironment Signatures as Biomarkers to Predict Early Recurrence of Stage Ia-b Lung Cancer. Frontiers in Oncology, 2021, 11, 680287.	1.3	18
18	Resistance mechanisms to osimertinib and emerging therapeutic strategies in nonsmall cell lung cancer. Current Opinion in Oncology, 2022, 34, 54-65.	1.1	18

#	ARTICLE	IF	CITATIONS
19	The Roles of Tissue-Resident Memory T Cells in Lung Diseases. <i>Frontiers in Immunology</i> , 2021, 12, 710375.	2.2	17
20	Impact of renin-angiotensin system inhibitors use on mortality in severe COVID-19 patients with hypertension: a retrospective observational study. <i>Journal of International Medical Research</i> , 2020, 48, 030006052097915.	0.4	16
21	Clinical treatment options for early-stage and advanced conjunctival melanoma. <i>Survey of Ophthalmology</i> , 2021, 66, 461-470.	1.7	13
22	Association between non-alcoholic fatty liver disease with the susceptibility and outcome of COVID-19: A retrospective study. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 11212-11220.	1.6	13
23	MiR-320a is associated with cisplatin resistance in lung adenocarcinoma and its clinical value in non-small cell lung cancer: A comprehensive analysis based on microarray data. <i>Lung Cancer</i> , 2020, 147, 193-197.	0.9	12
24	Surgical Outcomes After Neoadjuvant Chemoimmunotherapy for Resectable Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 684070.	1.3	12
25	Efficacy and Safety of Apatinib Plus Vinorelbine in Patients With Wild-Type Advanced Non-Small Cell Lung Cancer After Second-Line Treatment Failure. <i>JAMA Network Open</i> , 2020, 3, e201226.	2.8	11
26	Clinical Characteristics of Adult Febrile COVID-19 Patients and Predictors for Developing Severe Events. <i>Frontiers in Medicine</i> , 2020, 7, 324.	1.2	10
27	DNA methylation of hMLH1 correlates with the clinical response to cisplatin after a surgical resection in Non-small cell lung cancer. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 5457-63.	0.5	9
28	Adjuvant therapy for resected EGFR-mutant non-small-cell lung cancer. <i>Lancet Oncology</i> , The, 2018, 19, e124.	5.1	7
29	L-asparaginase-induced severe acute pancreatitis in an adult with extranodal natural killer/T-cell lymphoma, nasal type: A case report and review of the literature. <i>Oncology Letters</i> , 2014, 7, 1305-1307.	0.8	6
30	Hyperprogressive Disease After Immunotherapy: A Case Report of Pulmonary Enteric Adenocarcinoma. <i>Frontiers in Oncology</i> , 2022, 12, 799549.	1.3	6
31	The multidisciplinary team plays an important role in the prediction of small solitary pulmonary nodules: a propensity-score-matching study. <i>Annals of Translational Medicine</i> , 2019, 7, 740-740.	0.7	5
32	A prediction model integrated genomic alterations and immune signatures of tumor immune microenvironment for early recurrence of stage I NSCLC after curative resection. <i>Translational Lung Cancer Research</i> , 2022, 11, 24-42.	1.3	5
33	Radiotherapy with continued EGFR-TKIs for oligoprogressive disease in EGFR-mutated non-small cell lung cancer: A real-world study. <i>Cancer Medicine</i> , 2023, 12, 266-273.	1.3	5
34	Synchronous colorectal cancer and multiple myeloma with chest wall involvement: Is this a coincidence?. <i>Current Problems in Cancer</i> , 2017, 41, 413-418.	1.0	4
35	Metformin Combining PD-1 Inhibitor Enhanced Anti-Tumor Efficacy in STK11 Mutant Lung Cancer Through AXIN-1-Dependent Inhibition of STING Ubiquitination. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, 780200.	1.6	4
36	Different response to ALK inhibitors in EML4-ALK positive mediastinal cancer of unknown primary.. <i>Journal of Clinical Oncology</i> , 2020, 38, 104-104.	0.8	2

#	ARTICLE	IF	CITATIONS
37	Acquired Concurrent EGFR T790M and Driver Gene Resistance From EGFR-TKIs Hampered Osimertinib Efficacy in Advanced Lung Adenocarcinoma: Case Reports. <i>Frontiers in Pharmacology</i> , 2022, 13, 838247.	1.6	2
38	Radiotherapy with continued EGFR-TKIs for oligoprogressive disease in non-small cell lung cancer: A real-world study.. <i>Journal of Clinical Oncology</i> , 2019, 37, e20640-e20640.	0.8	1
39	Systemic Epstein-Barr virus-positive T/natural killer-cell lymphoproliferative disorder: a case report and review of literature. <i>International Journal of Clinical and Experimental Pathology</i> , 2014, 7, 6998-7002.	0.5	1
40	Primary mediastinal large B-cell lymphoma arising from thyroid in a renal recipient with Hashimoto's thyroiditis. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 5944-6.	0.5	1
41	Adjuvant EGFR tyrosine kinase inhibitors for patients with resected EGFR-mutated non-small-cell lung cancer: a network meta-analysis. <i>Future Oncology</i> , 2022, 18, 2695-2707.	1.1	1
42	Correlation of psychological distress with quality of life and efficacy of immune checkpoint inhibitors in patients with newly diagnosed stage IIIB-IV NSCLC.. <i>Journal of Clinical Oncology</i> , 2022, 40, 12001-12001.	0.8	1
43	Ground-glass opacity showed response to immunotherapy in cancer patients.. <i>Journal of Clinical Oncology</i> , 2022, 40, e14605-e14605.	0.8	1
44	LUX-Lung 7: is there enough data for a final conclusion?. <i>Lancet Oncology</i> , The, 2016, 17, e266-e267.	5.1	0
45	Occurrence of quadruple squamous cell carcinoma following allogeneic hematopoietic stem cell transplantation for leukemia: A case report. <i>Oncology Letters</i> , 2021, 21, 341.	0.8	0
46	Subgroup-level network meta-analysis for efficacy of first-line immunotherapy-based treatments in advanced non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9064-9064.	0.8	0
47	Identification of recurrence-associated gene signature and tumor immune microenvironment features in resected stage I NSCLC.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9080-9080.	0.8	0
48	Therapeutic efficacy comparison of six major EGFR-TKIs in non-small-cell lung cancer patients with an activating EGFR mutation: A network meta-analysis.. <i>Journal of Clinical Oncology</i> , 2019, 37, e20671-e20671.	0.8	0
49	Dramatic response to brigatinib in a lung adenocarcinoma patient harboring EML4-ALK fusion and a G1202R de novo gene mutation. <i>European Journal of Cancer</i> , 2022, 165, 154-156.	1.3	0